Valeant Pharmaceuticals International Inc. (NYSE:VRX)‘s stock had its “buy” rating reaffirmed by equities research analysts at Jefferies Group in a research report issued on Wednesday. They presently have a $22.00 target price on the specialty pharmaceutical company’s stock, down from their previous target price of $40.00. Jefferies Group’s price target suggests a potential upside of 30.80% from the company’s current price.

VRX has been the subject of a number of other research reports. RBC Capital Markets set a $36.00 price target on Valeant Pharmaceuticals International and gave the company a “hold” rating in a research report on Friday, August 19th. Morgan Stanley reissued a “positive” rating on shares of Valeant Pharmaceuticals International in a research report on Friday, August 19th. Rodman & Renshaw reissued a “buy” rating and issued a $90.00 target price on shares of Valeant Pharmaceuticals International in a research report on Thursday, July 28th. Royal Bank Of Canada decreased their target price on Valeant Pharmaceuticals International from $35.00 to $29.00 and set a “sector perform” rating for the company in a research report on Wednesday. Finally, Wells Fargo & Co. reissued an “underperform” rating on shares of Valeant Pharmaceuticals International in a research report on Tuesday, November 1st. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $40.18.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at 16.82 on Wednesday. The firm’s market cap is $5.85 billion. The firm has a 50-day moving average price of $22.29 and a 200-day moving average price of $25.33. Valeant Pharmaceuticals International has a 52 week low of $13.77 and a 52 week high of $119.87.

Valeant Pharmaceuticals International (NYSE:VRX) last released its quarterly earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 EPS for the quarter, missing analysts’ consensus estimates of $1.78 by $0.23. The business had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.49 billion. Valeant Pharmaceuticals International had a negative net margin of 22.17% and a positive return on equity of 41.02%. The company’s revenue for the quarter was down 11.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.74 EPS. On average, equities research analysts predict that Valeant Pharmaceuticals International will post $6.45 earnings per share for the current year.

Several large investors have recently modified their holdings of the company. FMR LLC boosted its stake in shares of Valeant Pharmaceuticals International by 185.4% in the second quarter. FMR LLC now owns 15,545,539 shares of the specialty pharmaceutical company’s stock valued at $313,087,000 after buying an additional 10,099,493 shares during the period. Paulson & CO. Inc. raised its position in Valeant Pharmaceuticals International by 44.6% in the second quarter. Paulson & CO. Inc. now owns 19,072,000 shares of the specialty pharmaceutical company’s stock valued at $384,110,000 after buying an additional 5,883,900 shares in the last quarter. Morgan Stanley raised its position in Valeant Pharmaceuticals International by 241.6% in the third quarter. Morgan Stanley now owns 5,967,745 shares of the specialty pharmaceutical company’s stock valued at $146,508,000 after buying an additional 4,220,573 shares in the last quarter. Hexavest Inc. raised its position in Valeant Pharmaceuticals International by 110.1% in the third quarter. Hexavest Inc. now owns 3,765,875 shares of the specialty pharmaceutical company’s stock valued at $92,429,000 after buying an additional 1,973,087 shares in the last quarter. Finally, Okumus Fund Management Ltd. raised its position in Valeant Pharmaceuticals International by 98.5% in the first quarter. Okumus Fund Management Ltd. now owns 3,722,464 shares of the specialty pharmaceutical company’s stock valued at $97,901,000 after buying an additional 1,846,864 shares in the last quarter. 64.39% of the stock is currently owned by hedge funds and other institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.